NCT01256658View on ClinicalTrials.gov

A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)

PHASE4CompletedINTERVENTIONAL
Enrollment

14,075

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Malaria
Interventions
DRUG

COA566

COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.

Trial Locations (3)

2208

Novartis Investigative Site, Burkina Faso

Unknown

Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou

Novartis Investigative site, Ouagadougou

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY